Sygnis SA

Equities

SYG

PLMODE000019

Biotechnology & Medical Research

End-of-day quote Warsaw S.E. Other stock markets 03:30:00 25/06/2024 am IST			5-day change	1st Jan Change
0.644 ^PLN	0.00%		+2.22%	-28.12%

15/05	Sygnis SA Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
14/02	Sygnis SA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Sygnis SA Reports Earnings Results for the Full Year Ended December 31, 2021

March 22, 2022 at 12:14 am IST

Sygnis SA reported earnings results for the full year ended December 31, 2021. For the full year, the company reported revenue was PLN 3.53 million compared to PLN 2.77 million a year ago. Net income was PLN 0.403616 million compared to PLN 0.303792 million a year ago.

Latest news about Sygnis SA

Sygnis SA Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Sygnis SA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/02	CI
Sygnis SA Reports Earnings Results for the Full Year Ended December 31, 2023	15/02	CI
Sygnis SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Sygnis SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Sygnis SA Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Sygnis SA Auditor Raises 'Going Concern' Doubt	20/23/20	CI
Sygnis SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI
Sygnis SA acquired majority stake in ZMorph sp. z o.o. from Warsaw Equity Group for PLN 3.64 Million.	29/22/29	CI
Sygnis SA Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13	CI
Sygnis SA Reports Earnings Results for the Full Year Ended December 31, 2021	22/22/22	CI
Sygnis SA Auditor Raises 'Going Concern' Doubt	21/22/21	CI
MODE S.A. will Change its Name to Sygnis SA	28/22/28	CI
MODE S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	10/21/10	CI
MODE S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021	12/21/12	CI
Mode S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021	14/21/14	CI
An unknown buyer acquired 14.92% stake in MODE S.A. from SETANTA Alternatywna Spólka Inwestycyjna Spólka Akcyjna.	18/18/18	CI

Chart Sygnis SA

Duration

Period

More charts

Company Profile

Sygnis SA is a Poland-based company, which egages in Research and Development (R&D) activities. The Company is active in four segments: Bioconvergence, Nanotechnology, Power Engineering, and New Incremental Technologies. Bioconvergence is a segment in which research is conducted to prevent the shortage of organs for transplants by bioprinting organs and creating bionic models for drug testing. The Nanotechnology segment is focused on using solutions from the field of photoelectron spectroscopy, and critical atomic force microscopy in casual products. The Power Engineering segment is focused on new methods of energy storage for renewable energy and other sources. New Incremental Technologies is focused on the development of solutions regarding 3D printing. The Company cooperates with over 85 specialists such as physicists, mechatronics, chemists, engineers, designers, and sociologists, and is involved in multiple projects.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SYGNIS SA	-28.12%	4.02M
MODERNA, INC.	+23.13%	46.93B
LONZA GROUP AG	+37.07%	39.08B
IQVIA HOLDINGS INC.	-8.73%	38.48B
ALNYLAM PHARMACEUTICALS, INC.	+28.09%	31.01B
CELLTRION, INC.	-12.26%	26.14B
ICON PUBLIC LIMITED COMPANY	+10.57%	25.88B
MEDPACE HOLDINGS, INC.	+32.23%	12.53B
BIO-TECHNE CORPORATION	-6.56%	11.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.56%	10.65B

Other Biotechnology & Medical Research